نتایج جستجو برای: insulin glargine

تعداد نتایج: 183258  

2012
Cécile Pierre-Eugene Patrick Pagesy Tuyet Thu Nguyen Marion Neuillé Georg Tschank Norbert Tennagels Cornelia Hampe Tarik Issad

BACKGROUND In diabetic patients, the pharmacokinetics of injected human insulin does not permit optimal control of glycemia. Fast and slow acting insulin analogues have been developed, but they may have adverse properties, such as increased mitogenic or anti-apoptotic signaling. Insulin/IGF1 hybrid receptors (IR/IGF1R), present in most tissues, have been proposed to transmit biological effects ...

Journal: :Endocrine journal 2006
Tomoaki Yoshihara Naoki Kumashiro Yoshie Kanazawa Tomoya Mita Yuko Sakurai Junko Kawai Michiko Abe Kayoko Motojima Kanako Hara Yuka Yamazaki Akio Kanazawa Shinya Miwa Fumihiko Sato Rei Kanno Tomoaki Shimizu Ken Sakai Hiroshi Uchino Hirotaka Watada Yasushi Tanaka Ryuzo Kawamori Takahisa Hirose

Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs to improve postprandial hyperglycemia in early type 2 diabetes. While mitiglinide enhances postprandial requirement of insulin, the efficacy of mitiglinide combined with insulin has yet to be established. We investigated the efficacy of mitigli...

Journal: :Diabetes care 2008
John C Pickup Eric Renard

Insulin pump therapy (continuous subcutaneous insulin infusion [CSII]) is now an established form of intensive insulin treatment. It is pertinent to ask, however, if multiple daily injection (MDI) regimens based on new long-acting insulin analogs such as glargine and detemir have now replaced the need for CSII. In type 1 diabetes, CSII reduces the frequency of severe hypoglycemia compared with ...

2014
A J Garber

Treat-to-target trial designs compare investigational insulins with a standard insulin. Treat-to-target trials force-titrate insulin dosages to achieve a prespecified treatment goal. With comparable glycaemic control, comparisons of safety endpoints such as hypoglycaemia can be made to establish the risk-benefit profile of the new insulin. Glargine versus NPH showed comparable A1C reductions; h...

2013
Dana G. Carroll

Address correspondence to Dana G. Carroll, PharmD, BCPS, CDE, 850 5th Avenue East, Tuscaloosa, AL 35401. Mixing Insulin Glargine With Rapid-Acting Insulin: A Review of the Literature Dana G. Carroll, PharmD, BCPS, CDE, and Lisa Meade, PharmD, CDE Purpose. To review the literature examining the mixing of insulin glargine with rapid-acting insulin (RAI). Methods. A literature search was conducted...

Journal: :Diabetes care 2014
Louise Bordeleau Natalia Yakubovich Gilles R Dagenais Julio Rosenstock Jeffrey Probstfield Pan Chang Yu Lars E Ryden Valdis Pirags Giatgen A Spinas Kare I Birkeland Robert E Ratner Jose A Marin-Neto Matyas Keltai Matthew C Riddle Jackie Bosch Salim Yusuf Hertzel C Gerstein

OBJECTIVE Epidemiologic studies linking insulin glargine and glucose-lowering therapies to cancers and n-3 fatty acids to cancer prevention have not been confirmed. We aimed to assess the effect of insulin glargine and n-3 fatty acids on incident cancers within the context of the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial. RESEARCH DESIGN AND METHODS The ORIGIN trial is...

Journal: :The Tohoku journal of experimental medicine 2015
Takaaki Murakami Takuo Nambu Tomoko Kato Yuki Matsuda Shin Yonemitsu Seiji Muro Shogo Oki

The combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and a long-acting insulin analogue is widely used in clinical practice. However, some patients fail to achieve lower postprandial hyperglycemia. Mitiglinide, a short-acting insulinotropic sulfonylurea receptor ligand, is effective for postprandial hyperglycemia. Recently, it has been reported that the combination therapy of mitiglini...

2015
Sorin Ioacara Cristian Guja Aura Reghina Sorina Martin Anca Sirbu Simona Fica

The study investigated the impact of insulin glargine exposure on cardiovascular mortality in type 2 diabetes patients with incident insulin initiation. All consecutive diabetes patients aged >40 years were screened at their first diabetes outpatient visit between 01/01/2001 and 12/31/2008 (n = 79869). Exclusion criteria restricted the cohort to 4990 incident insulin users, aged 40-79 years, wh...

Journal: :Lancet 2011
Bernard Zinman Greg Fulcher Paturi V Rao Nihal Thomas Lars A Endahl Thue Johansen Rebecka Lindh Andrew Lewin Julio Rosenstock Michel Pinget Chantal Mathieu

BACKGROUND Insulin degludec is a new basal insulin that forms soluble multihexamer assemblies after subcutaneous injection, resulting in an ultra-long action profile. This study aimed to assess efficacy and safety of insulin degludec injected once a day or three times a week compared with insulin glargine once a day in insulin-naive people with type 2 diabetes, who were inadequately controlled ...

Journal: :Diabetes care 2014
Louise Bordeleau Hertzel C Gerstein

Zanders et al. (1) provided a number of comments on our recently published article detailing the cancer outcomes of the Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial (2). They question the reported methodology in more detail. More specifically, they feel that the cancer outcome is a post hoc end point, that total daily dose of glargine should be used as opposed to total da...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید